• Je něco špatně v tomto záznamu ?

The effect of superdisintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin

B. Vraníková, J. Gajdziok, P. Doležel,

. 2017 ; 22 (2) : 138-147. [pub] 20150924

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17014254

CONTEXT: The preparation of liquisolid systems (LSS) represents a promising method for enhancing a dissolution rate and bioavailability of poorly soluble drugs. The release of the drug from LSS tablets is affected by many factors, including the disintegration time. OBJECTIVE: The evaluation of differences among LSS containing varying amounts and types of commercially used superdisintegrants (Kollidon® CL-F, Vivasol® and Explotab®). MATERIALS AND METHODS: LSS were prepared by spraying rosuvastatin solution onto Neusilin® US2 and further processing into tablets. Varying amounts of superdisintegrants were used and the differences among LSS were evaluated. The multiple scatter plot method was used to visualize the relationships within the obtained data. RESULTS AND DISCUSSION: All disintegrants do not showed negative effect on the flow properties of powder blends. The type and concentration of superdisintegrant had an impact on the disintegration time and dissolution profiles of tablets. Tablets with Explotab® showed the longest disintegration time and the smallest amount of released drug. Fastest disintegration and dissolution rate were observed in tablets containing Kollidon® CL-F (≥2.5% w/w). Also tablets with Vivasol® (2.5-4.0% w/w) showed fast disintegration and complete drug release. CONCLUSION: Kollidon® CL-F and Vivasol® in concentration ≥2.5% are suitable superdisintegrants for LSS with enhanced release of drug.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17014254
003      
CZ-PrNML
005      
20181011123626.0
007      
ta
008      
170413s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/10837450.2015.1089900 $2 doi
035    __
$a (PubMed)26401959
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vraníková, Barbora, $d 1987- $7 xx0228025 $u Department of Pharmaceutics, Faculty of Pharmacy , University of Veterinary and Pharmaceutical Sciences , Palackeho Trida 1/3 , Brno , Czech Republic.
245    14
$a The effect of superdisintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin / $c B. Vraníková, J. Gajdziok, P. Doležel,
520    9_
$a CONTEXT: The preparation of liquisolid systems (LSS) represents a promising method for enhancing a dissolution rate and bioavailability of poorly soluble drugs. The release of the drug from LSS tablets is affected by many factors, including the disintegration time. OBJECTIVE: The evaluation of differences among LSS containing varying amounts and types of commercially used superdisintegrants (Kollidon® CL-F, Vivasol® and Explotab®). MATERIALS AND METHODS: LSS were prepared by spraying rosuvastatin solution onto Neusilin® US2 and further processing into tablets. Varying amounts of superdisintegrants were used and the differences among LSS were evaluated. The multiple scatter plot method was used to visualize the relationships within the obtained data. RESULTS AND DISCUSSION: All disintegrants do not showed negative effect on the flow properties of powder blends. The type and concentration of superdisintegrant had an impact on the disintegration time and dissolution profiles of tablets. Tablets with Explotab® showed the longest disintegration time and the smallest amount of released drug. Fastest disintegration and dissolution rate were observed in tablets containing Kollidon® CL-F (≥2.5% w/w). Also tablets with Vivasol® (2.5-4.0% w/w) showed fast disintegration and complete drug release. CONCLUSION: Kollidon® CL-F and Vivasol® in concentration ≥2.5% are suitable superdisintegrants for LSS with enhanced release of drug.
650    _2
$a sloučeniny hliníku $x chemie $7 D017607
650    _2
$a anticholesteremika $x aplikace a dávkování $x chemie $7 D000924
650    _2
$a příprava léků $7 D004339
650    _2
$a uvolňování léčiv $7 D065546
650    _2
$a sloučeniny hořčíku $x chemie $7 D017616
650    _2
$a farmaceutické pomocné látky $x chemie $7 D010592
650    _2
$a povidon $x chemie $7 D011205
650    _2
$a rosuvastatin kalcium $x aplikace a dávkování $x chemie $7 D000068718
650    _2
$a silikáty $x chemie $7 D017640
650    _2
$a rozpustnost $7 D012995
650    _2
$a škrob $x analogy a deriváty $x chemie $7 D013213
650    _2
$a tablety $x chemie $7 D013607
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gajdziok, Jan $u a Department of Pharmaceutics, Faculty of Pharmacy , University of Veterinary and Pharmaceutical Sciences , Palackeho Trida 1/3 , Brno , Czech Republic.
700    1_
$a Doležel, Petr $u a Department of Pharmaceutics, Faculty of Pharmacy , University of Veterinary and Pharmaceutical Sciences , Palackeho Trida 1/3 , Brno , Czech Republic.
773    0_
$w MED00004889 $t Pharmaceutical development and technology $x 1097-9867 $g Roč. 22, č. 2 (2017), s. 138-147
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26401959 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20181011124117 $b ABA008
999    __
$a ok $b bmc $g 1200719 $s 975032
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 22 $c 2 $d 138-147 $e 20150924 $i 1097-9867 $m Pharmaceutical development and technology $n Pharm Dev Technol $x MED00004889
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...